Latest Information Update: 17 Jan 2007
At a glance
- Originator SuperGen
- Class Antianaemics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 17 Jan 2007 Discontinued - Phase-II for Anaemia in USA (unspecified route)
- 08 Jan 2001 No-Development-Reported for Anaemia in USA (Unknown route)
- 13 May 1998 Phase-II clinical trials for Anaemia in USA (Unknown route)